Purdue Pharma L.P

Eisai Co., Ltd. (CEO: Haruo Naito, “Eisai”) and Purdue Pharma L.P. (President and CEO: Craig Landau, MD “Purdue Pharma”) today announced that they will present data on their investigational sleep-wake regulation agent lemborexant (development code: E2006), in an oral presentation at the 43rd Annual Meeting of the Japanese Society of Sleep Research (JSSR), July 11-13, Sapporo, Japan Read More »

Eisai Co., Ltd. (CEO: Haruo Naito, “Eisai”) and Purdue Pharma L.P. (President and CEO: Craig Landau, “Purdue Pharma”) today presented the results of two key Phase 1 clinical studies of their investigational sleep/wake regulation agent lemborexant at the 32nd Annual Meeting of the Associated Professional Sleep Societies (SLEEP 2018), June 2-6, Baltimore, MD. Lemborexant is currently being studied for the potential treatment of multiple sleep disorders. Read More »

Just announced that John Renger, Ph.D., has been appointed Vice President, Head of Research & Development and Regulatory Affairs. He will be based in Stamford, Connecticut and report directly to President and CEO Craig Landau, MD. Read More »

Purdue Pharma's Colace product line and Senokot tablets will now come with new packaging. Read More »

Purdue Pharma L.P.'s Maria Barton has been promoted from deputy general counsel to general counsel. Read More »

Josie Martin has been named vice president of corporate affairs and communications for Purdue Pharma LP. Read More »

Purdue Pharma LP's Carrie Chomiak will be stepping up into a substantial business role as lead of over-the-counter product franchise for brands including Betadine microbicide antiseptics, Slow-Mag magnesium chloride supplements, Senokot laxative and Colace stool softener. Read More »

Teaming up to enhance North Carolina’s public health outcomes, Purdue Pharma of Stamford, Connecticut; nationwide Project Lazarus; and Safe Kids North Carolina recently entered a three-way collaboration via the North Carolina Disposal Initiative (NCDI). Read More »

Shionogi Inc. and Purdue Pharma L.P.'s Symproic 0.2 mg tablets C-II have been approved by the U.S. Food and Drug Administration for use as a once-daily oral peripherally-acting mu-opioid receptor antagonist medication in treating opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain. Read More »

Purdue Pharma LP has named Margaret Feltz vice president and chief ethics/compliance officer, reporting to President and CEO Mark Timney. Read More »

Shionogi & Co. Ltd., its subsidiary Shionogi Inc. and Purdue Pharma will launch Symproic, also known as naldemedine, to treat adult patients with chronic non-cancer pain who have opioid-induced constipation. Read More »